Correlation Between Fidelity Capital and Pharmaceuticals Ultrasector

Can any of the company-specific risk be diversified away by investing in both Fidelity Capital and Pharmaceuticals Ultrasector at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Fidelity Capital and Pharmaceuticals Ultrasector into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Fidelity Capital Income and Pharmaceuticals Ultrasector Profund, you can compare the effects of market volatilities on Fidelity Capital and Pharmaceuticals Ultrasector and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Fidelity Capital with a short position of Pharmaceuticals Ultrasector. Check out your portfolio center. Please also check ongoing floating volatility patterns of Fidelity Capital and Pharmaceuticals Ultrasector.

Diversification Opportunities for Fidelity Capital and Pharmaceuticals Ultrasector

0.59

Correlation Coefficient

Fidelity Capital  Pharmaceuticals Ultrasector

Very weak diversification

The 3 months correlation between Fidelity and Pharmaceuticals is 0.59. Overlapping area represents the amount of risk that can be diversified away by holding Fidelity Capital Income and Pharmaceuticals Ultrasector Pr in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Pharmaceuticals Ultrasector and Fidelity Capital is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Fidelity Capital Income are associated (or correlated) with Pharmaceuticals Ultrasector. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Pharmaceuticals Ultrasector has no effect on the direction of Fidelity Capital i.e., Fidelity Capital and Pharmaceuticals Ultrasector go up and down completely randomly.

Pair Corralation between Fidelity Capital and Pharmaceuticals Ultrasector

Assuming the 90 days horizon Fidelity Capital Income is expected to generate 0.25 times more return on investment than Pharmaceuticals Ultrasector. However, Fidelity Capital Income is 4.03 times less risky than Pharmaceuticals Ultrasector. It trades about -0.08 of its potential returns per unit of risk. Pharmaceuticals Ultrasector Profund is currently generating about -0.08 per unit of risk. If you would invest  1,031  in Fidelity Capital Income on December 4, 2024 and sell it today you would lose (19.00) from holding Fidelity Capital Income or give up 1.84% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Fidelity Capital Income  vs.  Pharmaceuticals Ultrasector Pr

Fidelity Capital Income

Risk-Adjusted Performance

Very Weak

Over the last 90 days Fidelity Capital Income has generated negative risk-adjusted returns adding no value to fund investors. In spite of fairly strong forward indicators, Fidelity Capital is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors.

Pharmaceuticals Ultrasector

Risk-Adjusted Performance

Very Weak

Over the last 90 days Pharmaceuticals Ultrasector Profund has generated negative risk-adjusted returns adding no value to fund investors. In spite of latest weak performance, the Fund's forward indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the fund investors.

Pair Trading with Fidelity Capital and Pharmaceuticals Ultrasector

The main advantage of trading using opposite Fidelity Capital and Pharmaceuticals Ultrasector positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Fidelity Capital position performs unexpectedly, Pharmaceuticals Ultrasector can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Pharmaceuticals Ultrasector will offset losses from the drop in Pharmaceuticals Ultrasector's long position.

The idea behind Fidelity Capital Income and Pharmaceuticals Ultrasector Profund pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.